The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2799 · Cited by 1,753
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147
Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011
Self-citationOsteoblast Programmed Cell Death (Apoptosis): Modulation by Growth Factors and Cytokines
Jilka, R. L., Weinstein, R. S., Bellido, T., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1998.13.5.793 · Cited by 578
Inhibition of Osteoblast Differentiation by Tumor Necrosis Factor-α*
Gilbert, L., He, X., Farmer, P., Boden, S., Kozlowski, M., Rubin, J., & Nanes, M. S. (2000) · Endocrinology · doi:10.1210/endo.141.11.7739 · Cited by 555
Cited by
Mechanical Stimulation of Bone in Vivo Reduces Osteocyte Expression of Sost/Sclerostin
Robling, A. G., Niziolek, P. J., Baldridge, L. A., Condon, K. W., Allen, M. R., Alam, I., Mantila, S. M., Gluhak-Heinrich, J., Bellido, T. M., Harris, S. E., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m705092200 · Cited by 1,350
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation
Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J. (2005) · The FASEB Journal · doi:10.1096/fj.05-4221fje · Cited by 965
SOST Is a Ligand for LRP5/LRP6 and a Wnt Signaling Inhibitor
Semënov, M., Tamai, K., & He, X. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504308200 · Cited by 771
Bellido, T., Ali, A. A., Gubrij, I., Plotkin, L. I., Fu, Q., O’Brien, C. A., Manolagas, S. C., & Jilka, R. L. (2005) · Endocrinology · doi:10.1210/en.2005-0239 · Cited by 641
Lin, C., Jiang, X., Dai, Z., Guo, X., Weng, T., Wang, J., Li, Y., Feng, G., Gao, X., & He, L. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090411 · Cited by 628
Sims, N. A., & Gooi, J. H. (2008) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2008.07.016 · Cited by 513
Sclerostin Stimulates Osteocyte Support of Osteoclast Activity by a RANKL-Dependent Pathway
Wijenayaka, A. R., Kogawa, M., Lim, H. P., Bonewald, L. F., Findlay, D. M., & Atkins, G. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025900 · Cited by 503
Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease
Loots, G. G., Kneissel, M., Keller, H., Baptist, M., Chang, J., Collette, N. M., Ovcharenko, D., Plajzer-Frick, I., & Rubin, E. M. (2005) · Genome Research · doi:10.1101/gr.3437105 · Cited by 442
Update on Wnt signaling in bone cell biology and bone disease
Monroe, D. G., McGee-Lawrence, M. E., Oursler, M. J., & Westendorf, J. J. (2012) · Gene · doi:10.1016/j.gene.2011.10.044 · Cited by 392
SOST/sclerostin, an osteocyte-derived negative regulator of bone formation
Bezooijen, R. L. V., Dijke, P. T., Papapoulos, S. E., & G.M. Löwik, C. W. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.02.005 · Cited by 367
Molecular aspects of fracture healing:Which are the important molecules?
Tsiridis, E., Upadhyay, N., & Giannoudis, P. (2007) · Injury · doi:10.1016/j.injury.2007.02.006 · Cited by 365
Hellstein, J. W., Adler, R. A., Edwards, B., Jacobsen, P. L., Kalmar, J. R., Koka, S., Migliorati, C. A., & Ristic, H. (2011) · The Journal of the American Dental Association · doi:10.14219/jada.archive.2011.0108 · Cited by 363
Pathogenesis of bone disease in multiple myeloma: from bench to bedside
Terpos, E., Ntanasis-Stathopoulos, I., Gavriatopoulou, M., & Dimopoulos, M. A. (2018) · Blood Cancer Journal · doi:10.1038/s41408-017-0037-4 · Cited by 354
Wnt/β-catenin signaling components and mechanisms in bone formation, homeostasis, and disease
Hu, L., Chen, W., Qian, A., & Li, Y.-P. (2024) · Bone Research · doi:10.1038/s41413-024-00342-8 · Cited by 359
Sclerostin: Current Knowledge and Future Perspectives
Moester, M. J. C., Papapoulos, S. E., Löwik, C. W. G. M., & van Bezooijen, R. L. (2010) · Calcified Tissue International · doi:10.1007/s00223-010-9372-1 · Cited by 332
Multiple functions of Osterix are required for bone growth and homeostasis in postnatal mice
Zhou, X., Zhang, Z., Feng, J. Q., Dusevich, V. M., Sinha, K., Zhang, H., Darnay, B. G., & de Crombrugghe, B. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912855107 · Cited by 317
Mirza, F. S., Padhi, I. D., Raisz, L. G., & Lorenzo, J. A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2283 · Cited by 311
Current concepts in the biology of orthodontic tooth movement
Masella, R. S., & Meister, M. (2006) · American Journal of Orthodontics and Dentofacial Orthopedics · doi:10.1016/j.ajodo.2005.12.013 · Cited by 306
Proteomics Characterization of Extracellular Space Components in the Human Aorta
Didangelos, A., Yin, X., Mandal, K., Baumert, M., Jahangiri, M., & Mayr, M. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m110.001693 · Cited by 287
Circulating Sclerostin Levels and Bone Turnover in Type 1 and Type 2 Diabetes
Gennari, L., Merlotti, D., Valenti, R., Ceccarelli, E., Ruvio, M., Pietrini, M. G., Capodarca, C., Franci, M. B., Campagna, M. S., Calabrò, A., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2958 · Cited by 272
Osteocytic signalling pathways as therapeutic targets for bone fragility
Plotkin, L. I., & Bellido, T. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.71 · Cited by 206
Kamiya, N., Kobayashi, T., Mochida, Y., Yu, P. B., Yamauchi, M., Kronenberg, H. M., & Mishina, Y. (2010) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090806 · Cited by 198
Villareal, D. T., Fontana, L., Das, S. K., Redman, L., Smith, S. R., Saltzman, E., Bales, C., Rochon, J., Pieper, C., Huang, M., et al. (2016) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2701 · Cited by 191
“One such factor is sclerostin, a protein secreted by osteocytes in states of unloading (eg, weight loss) to inhibit Wnt/b-catenin signaling and bone formation.((39,40)) A recent study reported increase in sclerostin with weight loss that was prevented by exercise.”
BackgroundArmamento-Villareal, R., Sadler, C., Napoli, N., Shah, K., Chode, S., Sinacore, D. R., Qualls, C., & Villareal, D. T. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1560 · Cited by 158
“Sclerostin is a secreted Wnt antagonist that regulates bone mass by binding to LRP5/6 and inhibiting the canonical Wnt/ b-catenin signaling, resulting in inhibition of osteoblastic proliferation and differentiation, thus reduced bone formation.((7,8)) Animal studies indicate an increase in sclerostin levels in experim…”
BackgroundOminsky, M. S., Brown, D. L., Van, G., Cordover, D., Pacheco, E., Frazier, E., Cherepow, L., Higgins-Garn, M., Aguirre, J. I., Wronski, T. J., et al. (2015) · Bone · doi:10.1016/j.bone.2015.08.007 · Cited by 93
The Role of Sclerostin in Bone and Ectopic Calcification
De Maré, A., D’Haese, P. C., & Verhulst, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093199 · Cited by 45
Non-Coding RNAs in Multiple Myeloma Bone Disease Pathophysiology
Raimondi, L., De Luca, A., Giavaresi, G., Raimondo, S., Gallo, A., Taiana, E., Alessandro, R., Rossi, M., Neri, A., Viglietto, G., et al. (2020) · Non-Coding RNA · doi:10.3390/ncrna6030037 · Cited by 16
Metadata
- Authors
- Sutherland, M. K., Geoghegan, J. C., Yu, C., Turcott, E., Skonier, J. E., Winkler, D. G., & Latham, J. A.
- Venue
- Bone
- Publisher
- Elsevier BV
- Published
- 2004-10
- Volume
- 35
- Issue
- 4
- Pages
- 828-835
- ISSN
- 1873-2763 (ISSN-L)
- 8756-3282
- OpenAlex
- W2003457351
- Cited by
- 238
- References
- 5
- FWCI
- 2.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.